| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5510383 | ALCON PHARMS LTD | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
Aug, 2013
(10 years ago) | |
| US5889052 | ALCON PHARMS LTD | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
Dec, 2014
(9 years ago) | |
| US5631287 | ALCON PHARMS LTD | Storage-stable prostaglandin compositions |
Dec, 2014
(9 years ago) | |
| US6011062 | ALCON PHARMS LTD | Storage-stable prostaglandin compositions |
Dec, 2014
(9 years ago) | |
| US5849792 | ALCON PHARMS LTD | Storage-stable prostaglandin compositions |
Dec, 2014
(9 years ago) | |
Travatan is owned by Alcon Pharms Ltd.
Travatan contains Travoprost.
Travatan has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Travatan are:
- US5510383
- US5889052
- US5631287
- US6011062
- US5849792
Travatan was authorised for market use on 16 March, 2001.
Travatan is available in solution/drops;ophthalmic dosage forms.
Travatan can be used as method of stabilizing prostaglandin, method for treating glaucoma and ocular hypertension.
The generics of Travatan are possible to be released after 22 December, 2014.
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 16 March, 2001
Treatment: Method for treating glaucoma and ocular hypertension; Method of stabilizing prostaglandin
Dosage: SOLUTION/DROPS;OPHTHALMIC
TRAVATAN family patents
